Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

72.37EUR
18 Jan 2018
Change (% chg)

-- (--)
Prev Close
€72.37
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,124,700
52-wk High
€92.97
52-wk Low
€71.06

Latest Key Developments (Source: Significant Developments)

Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data From Pivotal Phase 3 Palisade Trial Of AR101 For Peanut Allergy
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS - PALISADE COMPLETED IN 2017; TOPLINE RESULTS ANTICIPATED IN FEBRUARY.AIMMUNE THERAPEUTICS INC - AR101 BLA SUBMISSION EXPECTED AT END OF 2018.AIMMUNE THERAPEUTICS ANNOUNCES 2018 OUTLOOK, INCLUDING UPCOMING DATA FROM PIVOTAL PHASE 3 PALISADE TRIAL OF AR101 FOR PEANUT ALLERGY.AIMMUNE THERAPEUTICS - ARTEMIS TRIAL IS ON TRACK TO COMPLETE ENROLLMENT IN Q1 OF 2018, EXPECTS DATA FROM ARTEMIS IN EARLY 2019.AIMMUNE THERAPEUTICS INC - ENDED 2017 WITH ABOUT $182 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DEC 31, 2017.AIMMUNE THERAPEUTICS INC- 2018 PLANS INCLUDE INITIATION OF ARC005 CLINICAL TRIAL OF AR101 FOR PEANUT ALLERGY IN YOUNG CHILDREN AGES 6-48 MONTHS.AIMMUNE THERAPEUTICS - 2018 PLANS ALSO INCLUDE INITIATION, WITH REGENERON AND SANOFI, OF PHASE 2 CLINICAL TRIAL OF AR101 AND ADJUNCTIVE DUPILUMAB.AIMMUNE - ALSO EXPECTS TO FILE IND APPLICATION FOR EGG ALLERGY PROGRAM IN 2018, CONTINUE WORK TOWARD FILING IND FOR WALNUT ALLERGY IN 2019.  Full Article

Regeneron Pharma Says Enter Letter Agreement Relating To Immuno-Oncology License,Collaboration Agreement With Sanofi
Monday, 8 Jan 2018 07:13am EST 

Jan 8 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON PHARMACEUTICALS-ON JAN 7,ENTERED LETTER AGREEMENT RELATING TO IMMUNO-ONCOLOGY LICENSE,COLLABORATION AGREEMENT WITH SANOFI BIOTECHNOLOGY SAS​.REGENERON PHARMACEUTICALS-PURSUANT TO LETTER AGREEMENT, CO, SANOFI SAS, AGREED TO INCREASE REGN2810 BUDGET AMOUNT TO $1.640 BILLION.REGENERON -ENTERED LETTER AGREEMENT ALSO RELATING TO AMONG OTHERS​, THE INVESTOR AGREEMENT DATED AS OF JAN 11, 2014, WITH SANOFI - SEC FILING.REGENERON PHARMACEUTICALS INC - ‍ ALSO AGREED TO REVISE REGN2810 GLOBAL DEVELOPMENT PLAN AND REGN2810 GLOBAL DEVELOPMENT BUDGET.  Full Article

Sanofi And Alnylam Pharmaceuticals Enter Into Partnership
Monday, 8 Jan 2018 02:23am EST 

Jan 8 (Reuters) - SANOFI SA ::AND ALNYLAM, ANNOUNCED ON SUNDAY STRATEGIC RESTRUCTURING OF RNAI THERAPEUTICS RARE DISEASE ALLIANCE.SANOFI WILL OBTAIN GLOBAL DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO FITUSIRAN.GLOBAL COMMERCIALIZATION OF FITUSIRAN, UPON APPROVAL, WILL BE DONE BY SANOFI GENZYME.ALNYLAM WILL RECEIVE ROYALTIES BASED ON NET SALES OF FITUSIRAN PRODUCTS.ALNYLAM TO OBTAIN GLOBAL DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO ITS INVESTIGATIONAL RNAI THERAPEUTICS PROGRAMS FOR THE TREATMENT OF ATTR AMYLOIDOSIS, INCLUDING PATISIRAN AND ALN-TTRSC02.SANOFI WILL RECEIVE ROYALTIES BASED ON NET SALES OF THESE ATTR AMYLOIDOSIS PRODUCTS.  Full Article

Evotec, Apeiron Biologics receive milestone payment from Sanofi
Monday, 8 Jan 2018 01:31am EST 

Jan 8 (Reuters) - Evotec Ag ::SAYS ‍EVOTEC AND APEIRON ACHIEVE FIRST MILESTONE IN IMMUNO-ONCOLOGY ALLIANCE WITH SANOFI​.SAYS ‍MILESTONE PAYMENT OF EUR 3 M WILL BE SPLIT EQUALLY BETWEEN TWO BIOTECH COMPANIES​.SAYS ‍SUCCESS PAYMENT WAS TRIGGERED WHEN PARTNERS SUCCESSFULLY ADVANCED AN UNDISCLOSED, NOVEL IMMUNO-ONCOLOGY SMALL MOLECULE INTO LATE-STAGE PRE-CLINICAL DEVELOPMENT​.SAYS ‍UNDER ALLIANCE, THREE COMPANIES WORK TOGETHER TO IDENTIFY SMALL MOLECULE LEADS AND TARGETS FOR NEXT-GENERATION THERAPIES IN IMMUNO-ONCOLOGY​.  Full Article

Sanofi Joins Forces With BIOASTER To Improve The Search For Next-Generation Vaccine Candidates
Thursday, 21 Dec 2017 12:38pm EST 

Dec 21 (Reuters) - SANOFI ::JOINS FORCES WITH BIOASTER TO IMPROVE THE SEARCH FOR NEXT-GENERATION VACCINE CANDIDATES.  Full Article

‍Sanofi, Alnylam submit marketing authorization application to EMA for Patisiran
Monday, 18 Dec 2017 07:06am EST 

Dec 18 (Reuters) - Sanofi statement::Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis.‍Patisiran Marketing Authorization Application to be reviewed under accelerated assessment.Sanofi Genzyme is currently preparing regulatory filings for patisiran in Japan, Brazil and other countries, with submissions expected to begin in the first half of 2018. .Pending regulatory approvals, Alnylam will commercialize patisiran in the U.S., Canada and Western Europe, with Sanofi Genzyme commercializing the product in the rest of the world, including certain Central and Eastern European countries of the European Union. .​.  Full Article

Sanofi says FDA Lifts Clinical Hold On Fitusiran
Friday, 15 Dec 2017 07:00am EST 

Dec 15 (Reuters) - SANOFI ::REG-SANOFI: FDA LIFTS CLINICAL HOLD ON FITUSIRAN.CLINICAL TRIAL DOSING TO RESUME AROUND YEAR-END 2017.  Full Article

FDA Lifts Clinical Hold On Fitusiran
Friday, 15 Dec 2017 07:00am EST 

Dec 15 (Reuters) - Alnylam Pharmaceuticals Inc ::FDA LIFTS CLINICAL HOLD ON FITUSIRAN.FDA LIFTS CLINICAL HOLD ON FITUSIRAN.ALNYLAM PHARMACEUTICALS INC - CLINICAL TRIAL DOSING TO RESUME AROUND YEAR-END 2017.ALNYLAM - FDA LIFTED HOLD ON CLINICAL STUDIES WITH FITUSIRAN, INCLUDING PHASE 2 OPEN-LABEL EXTENSION STUDY, ATLAS PHASE 3 PROGRAM.ALNYLAM PHARMA - FDA HAS APPROVED PROTOCOL AMENDMENTS, OTHER UPDATED CLINICAL MATERIALS FOR FITUSIRAN STUDIES.ALNYLAM - CO, FDA HAD PREVIOUSLY REACHED ALIGNMENT ON NEW CLINICAL RISK MITIGATION MEASURES.  Full Article

Mylan Announces U.S. Regulator's Review Proceedings On All Claims Against Sanofi's Lantus Patents
Thursday, 14 Dec 2017 07:30am EST 

Dec 14 (Reuters) - Mylan Nv ::MYLAN ANNOUNCES THE U.S. PATENT AND TRADEMARK APPEAL BOARD INSTITUTES INTER PARTES REVIEW PROCEEDINGS ON ALL CLAIMS AGAINST SANOFI'S LANTUS® PATENTS.MYLAN SAYS U.S. PTAB INSTITUTED IPR PROCEEDINGS ON CLAIMS AGAINST 2 ORANGE BOOK-LISTED PATENTS OWNED BY SANOFI FOR LANTUS 100 UNITS/ML.  Full Article

Sanofi says to rely more on immunology to meet long term targets
Wednesday, 13 Dec 2017 02:57am EST 

Dec 13 (Reuters) - Sanofi ::CEO Olivier Brandicourt says the company is "on track" regarding the planned sale of its European generic drugs unit.says the company will rely more on immunology to meet its long term financial targets following setbacks with cholesterol drug Praluent and dengue vaccine Dengvaxia.  Full Article

LPC-Bankers line up €1.2bn debt for Sanofi’s European drugs unit sale

LONDON, Jan 18 Bankers have put together around €1.2bn of debt financing to back a potential sale of French drug maker Sanofi’s European generic drug business as the sale process kicks off, banking sources said.